Evotec Announces Dr. Craig Johnstone’s Departure as Chief Operating Officer

Evotec Announces Dr. Craig Johnstone’s Departure as Chief Operating Officer

(IN BRIEF) Evotec SE announced that Dr. Craig Johnstone, the company’s Chief Operating Officer, will step down on 31 December 2024. Dr. Johnstone joined Evotec in 2012 and held various leadership roles, including Global Head of Integrated Drug Discovery and COO. The Supervisory Board and Management Board expressed gratitude for his contributions over the past 12 years. Going forward, the COO responsibilities will be shared internally by the Global Operations Leadership Team until a new organizational structure is established following a strategic review.

(PRESS RELEASE) HAMBURG, 2-Dec-2024 — /EuropaWire/ — Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has confirmed that Dr. Craig Johnstone, the company’s Chief Operating Officer, will step down effective 31 December 2024. Dr. Johnstone has been with Evotec since 2012, initially joining as SVP Drug Discovery and Innovation Efficiency, and later serving as President and Site Head of Evotec (France) SAS in 2015. He was appointed Global Head of Integrated Drug Discovery in 2017 before becoming COO and joining the Management Board in January 2019.

A Legacy of Leadership and Dedication

Prof. Dr. Iris Löw-Friedrich, Chairwoman of Evotec’s Supervisory Board, expressed deep appreciation for Dr. Johnstone’s contributions:
“Craig’s leadership has been pivotal in shaping Evotec, especially in Global Operations. On behalf of the Supervisory Board, I extend our heartfelt thanks for his dedication over the past 12 years. We wish him continued success in his future endeavors.”

Dr. Johnstone himself reflected on his tenure, saying,
“I am truly grateful for the opportunity to work alongside such talented and dedicated colleagues. Your passion and commitment to science have been inspiring, and I wish Evotec much success in the years ahead.”

Internal Transition and Future Structure

Dr. Christian Wojczewski, CEO of Evotec, also expressed his gratitude:
“Craig’s leadership and passion have played a crucial role in Evotec’s success. We thank him for his tireless commitment and wish him the very best in his next chapter.”

In light of Dr. Johnstone’s departure, the COO’s responsibilities will be temporarily distributed across Evotec’s Global Operations Leadership Team. The company also noted that a new organizational structure will be introduced following its ongoing Strategic Review.

About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.

Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Media Contact:

Investor Relations:
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com

SOURCE: Evotec